Matrix metalloproteinase-9: Dual role and temporal profile in intracerebral hemorrhage

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 10, 2014, Pages 2498-2505

  Chang, Jason J ^a   Emanuel, Benjamin A ^a   Mack, William J ^b   Tsivgoulis, Giorgios ^c,d   Alexandrov, Andrei V ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Gelatinase B; intracerebral hemorrhage; Matrix metalloproteinase; Neuroprotection; Perihematomal edema blood brain barrier

Indexed keywords

GELATINASE B; MINOCYCLINE; VASCULOTROPIN; MATRIX METALLOPROTEINASE INHIBITOR; NEUROPROTECTIVE AGENT;

ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ANIMAL; BRAIN EDEMA; CEREBRAL HEMORRHAGE; COMPLICATION; DRUG EFFECTS; HEMATOMA; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; TIME;

ANIMALS; APOPTOSIS; BRAIN EDEMA; CEREBRAL HEMORRHAGE; HEMATOMA; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NEUROPROTECTIVE AGENTS; TIME FACTORS;

EID: 84923307978     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2014.07.005     Document Type: Review

References (58)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013;127:e6-e245.
2. Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology 2006;66:1182-1186.
3. Fogelholm R, Murros K, Rissanen A, et al. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry 2005;76:1534-1538.
4. Belur PK,Chang JJ,HeS, et al.Emerging experimental therapies for intracerebral hemorrhage: targeting mechanisms of secondary brain injury. Neurosurg Focus 2013;34:E9.
5. Mun-Bryce S, Wilkerson A, Pacheco B, et al. Depressed cortical excitability and elevated matrix metalloproteinases in remote brain regions following intracerebral hemorrhage. Brain research 2004;1026:227-234.
6. Qureshi AI, Suri MF, Ostrow PT, et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery 2003;52:1041-1047.
7. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997;28:1-5.
8. Lampl Y, Gilad R, Eshel Y, et al. Neurological and functional outcome in patients with supratentorial hemorrhages. A prospective study. Stroke 1995;26:2249-2253.
9. Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059-1064.
10. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66:1175-1181.
11. Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CTangiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012;11:307-314.
12. Huynh TJ, Demchuk AM, Dowlatshahi D, et al. Spot sign number is the most important spot sign characteristic for predicting hematoma expansion using first-pass computed tomography angiography: analysis from the PREDICT study. Stroke 2013;44:972-977.
13. Brouwers HB, Falcone GJ, McNamara KA, et al. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage. Neurocrit Care 2012;17:421-428.
14. Anderson CS, Heeley E, Huang Y, et al. Rapid bloodpressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355-2365.
15. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med 2010; 38:637-648.
16. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. New Engl J Med 2005;352:777-785.
17. Diringer MN, Skolnick BE, Mayer SA, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39:850-856.
18. Diringer MN, Skolnick BE, Mayer SA, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010;41:48-53.
19. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. New Engl J Med 2008; 358:2127-2137.
20. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
21. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-742.
22. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005; 6:931-944.
23. Gottschall PE, Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995;64:1513-1520.
24. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 2006;37:1399-1406.
25. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107:598-603.
26. Horstmann S, Su Y, Koziol J, et al. MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage. J Neurol Sci 2006;251:82-86.
27. Lee JM, Yin K, Hsin I, et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 2005;229-230:249-254.
28. Abilleira S, Montaner J, Molina CA, et al. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99:65-70.
29. Jung S, Moon KS, Jung TY, et al. Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage. J Neurooncol 2006;76:257-263.
30. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia 2002;39:279-291.
31. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998;18:1163-1172.
32. Barr TL, Latour LL, Lee KY, et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 2010; 41:e123-e128.
33. Lee CZ, Xue Z, Zhu Y, et al. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factorinduced intracerebral hemorrhage. Stroke 2007; 38:2563-2568.
34. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-285.
35. Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003;84:3-9.
36. Lee KR, Kawai N, Kim S, et al. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 1997;86:272-278.
37. Kawakita K, Kawai N, Kuroda Y, et al. Expression of matrix metalloproteinase-9 in thrombin-induced brain edema formation in rats. J Stroke Cerebrovasc Dis 2006; 15:88-95.
38. Xue M, Hollenberg MD, Demchuk A, et al. Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhagemediated neurotoxicity in mice. Stroke 2009;40: 2199-2204.
39. Wu J, Yang S, Xi G, et al. Minocycline reduces intracerebral hemorrhage-induced brain injury. Neurol Res 2009; 31:183-188.
40. Grossetete M, Rosenberg GA. Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse. J Cereb Blood Flow Metab 2008; 28:752-763.
41. Wang J, Tsirka SE. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005;128(Pt 7):1622-1633.
42. Tang J, Liu J, Zhou C, et al. MMP-9 deficiency enhances collagenase-induced intracerebral hemorrhage and brain injury in mutant mice. J Cereb Blood Flow Metab 2004; 24:1133-1145.
43. Xue M, Hollenberg MD, Yong VW. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006;26:10281-10291.
44. Lei C, Lin S, Zhang C, et al. Activation of cerebral recovery by matrix metalloproteinase-9 after intracerebral hemorrhage. Neuroscience 2013;230:86-93.
45. Castellazzi M, Tamborino C, De Santis G, et al. Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage. Acta Neurochir Suppl 2010;106:137-140.
46. Alvarez-Sabin J, Delgado P, Abilleira S, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004; 35:1316-1322.
47. Wu H, Zhang Z, Hu X, et al. Dynamic changes of inflammatory markers in brain after hemorrhagic stroke in humans: a postmortem study. Brain Res 2010;1342:111-117.
48. Li N, Liu YF, Ma L, et al. Association ofmolecularmarkers with perihematomal edema and clinical outcome in intracerebral hemorrhage. Stroke 2013;44:658-663.
49. Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997;48:921-926.
50. Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169:337-352.
51. ShiW,Wang Z, Pu J, et al. Changes of blood-brain barrier permeability following intracerebral hemorrhage and the therapeutic effect of minocycline in rats. Acta Neurochir Suppl 2011;110(Pt 2):61-67.
52. Wasserman JK, Schlichter LC. Minocycline protects the blood-brain barrier and reduces edema following intracerebral hemorrhage in the rat. Exp Neurol 2007;207: 227-237.
53. Zhao F, Hua Y, He Y, et al. Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhage. Stroke 2011;42:3587-3593.
54. Wu J, Yang S, Hua Y, et al. Minocycline attenuates brain edema, brain atrophy and neurological deficits after intracerebral hemorrhage. Acta Neurochir Suppl 2010; 106:147-150.
55. Fagan SC, Waller JL, Nichols FT, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke 2010;41:2283-2287.
56. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-1410.
57. Switzer JA, Hess DC, Ergul A, et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 2011; 42:2633-2635.
58. Kohler E, Prentice DA, Bates TR, et al. Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stroke 2013;44:2493-2499.